Tags

Type your tag names separated by a space and hit enter

Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome.
Anal Cell Pathol (Amst). 2020; 2020:1939768.AC

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent responsible for the development of a new coronavirus disease (COVID-19), is a highly transmittable virus which, in just ten months, infected more than 40 million people in 214 countries worldwide. After inhalation, aerosols containing SARS-CoV-2 penetrate to the depths of the lungs and cause severe pneumonia, alveolar injury, and life-threatening acute respiratory distress syndrome (ARDS). Since there are no specific drugs or vaccines available to cure or prevent COVID-19 infection and COVID-19-related ARDS, a new therapeutic agent which will support oxygen supply and, at the same time, efficiently alleviate SARS-CoV-2-induced lung inflammation is urgently needed. Due to their potent immuno- and angiomodulatory characteristics, mesenchymal stem cells (MSCs) may increase oxygen supply in the lungs and may efficiently alleviate ongoing lung inflammation, including SARS-CoV-2-induced ARDS. In this review article, we described molecular mechanisms that are responsible for MSC-based modulation of immune cells which play a pathogenic role in the development of SARS-CoV-2-induced ARDS and we provided a brief outline of already conducted and ongoing clinical studies that increase our understanding about the therapeutic potential of MSCs and their secretome in the therapy of COVID-19-related ARDS.

Authors+Show Affiliations

Regenerative Processing Plant, LLC, 34176 US Highway 19 N Palm Harbor, Palm Harbor, Florida, USA.Department of Infectious Diseases, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovica 69, 34000 Kragujevac, Serbia.Institute of Anatomy, University of Bern, 2 Baltzerstrasse, 3012 Bern, Switzerland.Department for Microbiology and Immunology, Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 69 Svetozar Markovic Street, Kragujevac, Serbia.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

33274176

Citation

Harrell, Carl Randall, et al. "Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome." Analytical Cellular Pathology (Amsterdam), vol. 2020, 2020, p. 1939768.
Harrell CR, Jovicic BP, Djonov V, et al. Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome. Anal Cell Pathol (Amst). 2020;2020:1939768.
Harrell, C. R., Jovicic, B. P., Djonov, V., & Volarevic, V. (2020). Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome. Analytical Cellular Pathology (Amsterdam), 2020, 1939768. https://doi.org/10.1155/2020/1939768
Harrell CR, et al. Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome. Anal Cell Pathol (Amst). 2020;2020:1939768. PubMed PMID: 33274176.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome. AU - Harrell,Carl Randall, AU - Jovicic,Biljana Popovska, AU - Djonov,Valentin, AU - Volarevic,Vladislav, Y1 - 2020/11/20/ PY - 2020/06/10/received PY - 2020/11/06/accepted PY - 2020/12/4/entrez PY - 2020/12/5/pubmed PY - 2020/12/15/medline SP - 1939768 EP - 1939768 JF - Analytical cellular pathology (Amsterdam) JO - Anal Cell Pathol (Amst) VL - 2020 N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent responsible for the development of a new coronavirus disease (COVID-19), is a highly transmittable virus which, in just ten months, infected more than 40 million people in 214 countries worldwide. After inhalation, aerosols containing SARS-CoV-2 penetrate to the depths of the lungs and cause severe pneumonia, alveolar injury, and life-threatening acute respiratory distress syndrome (ARDS). Since there are no specific drugs or vaccines available to cure or prevent COVID-19 infection and COVID-19-related ARDS, a new therapeutic agent which will support oxygen supply and, at the same time, efficiently alleviate SARS-CoV-2-induced lung inflammation is urgently needed. Due to their potent immuno- and angiomodulatory characteristics, mesenchymal stem cells (MSCs) may increase oxygen supply in the lungs and may efficiently alleviate ongoing lung inflammation, including SARS-CoV-2-induced ARDS. In this review article, we described molecular mechanisms that are responsible for MSC-based modulation of immune cells which play a pathogenic role in the development of SARS-CoV-2-induced ARDS and we provided a brief outline of already conducted and ongoing clinical studies that increase our understanding about the therapeutic potential of MSCs and their secretome in the therapy of COVID-19-related ARDS. SN - 2210-7185 UR - https://www.unboundmedicine.com/medline/citation/33274176/Therapeutic_Potential_of_Mesenchymal_Stem_Cells_and_Their_Secretome_in_the_Treatment_of_SARS_CoV_2_Induced_Acute_Respiratory_Distress_Syndrome_ L2 - https://doi.org/10.1155/2020/1939768 DB - PRIME DP - Unbound Medicine ER -